They also stated that an increase in FIBTEM MCF (>25 mm) can predict thromboembolic complications in hepatocellular carcinoma and in patients with pre-existing thrombophilic factors (high lupus anticoagulant, and/or positive Factor V Leiden mutation). The gene discussed is F5; the disease is hepatocellular carcinoma.